Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2026)
Rezolute's (RZLT) quarterly Total Non-Current Liabilities came in at $8.1 million in Q1 2026, down 30.55% year-on-year from $11.7 million in Q1 2025, and down 20.01% quarter-over-quarter from $10.1 million in Q4 2025.
Rezolute (RZLT) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Rezolute has disclosed Total Non-Current Liabilities across 14 years of filings, most recently posting $8.1 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $8.1 million, down 30.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (down 30.55% YoY), and the FY2025 annual result was $12.9 million, up 14.46% from the prior year.
- Total Non-Current Liabilities came in at $8.1 million for Q1 2026 at Rezolute, down from $10.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $17.3 million in Q1 2022 to a low of $2.5 million in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $10.0 million (2023), against an average of $9.8 million.
- Across the five-year window, Total Non-Current Liabilities slumped 85.28% in 2022 and soared 263.56% in 2023, its largest moves.
- Rezolute's Total Non-Current Liabilities stood at $8.5 million in 2022, then climbed by 17.06% to $10.0 million in 2023, then advanced by 19.88% to $11.9 million in 2024, then fell by 15.02% to $10.1 million in 2025, then dropped by 20.01% to $8.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $8.1 million (Q1 2026), $10.1 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Rezolute | 520.13 Mn | 520.13 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 10.15 Mn |
| Sep 30, 2025 | 11.01 Mn |
| Jun 30, 2025 | 12.90 Mn |
| Mar 31, 2025 | 11.69 Mn |
| Dec 31, 2024 | 11.94 Mn |
| Sep 30, 2024 | 9.52 Mn |
| Jun 30, 2024 | 11.27 Mn |
| Mar 31, 2024 | 16.42 Mn |
| Dec 31, 2023 | 9.96 Mn |
| Sep 30, 2023 | 9.01 Mn |
| Jun 30, 2023 | 7.14 Mn |
| Mar 31, 2023 | 6.44 Mn |
| Dec 31, 2022 | 8.51 Mn |
| Sep 30, 2022 | 2.48 Mn |
| Jun 30, 2022 | 2.54 Mn |
| Mar 31, 2022 | 17.27 Mn |
| Dec 31, 2021 | 20.76 Mn |
| Sep 30, 2021 | 16.83 Mn |
| Jun 30, 2021 | 16.12 Mn |